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BACKGROUND: Various digestive tract procedures effectively improve metabolic syndrome, especially the control of
type 2 diabetes mellitus. Very good metabolic results have been shown with vertical gastrectomy and entero-
omentectomy; however, the metabolic effects of an isolated entero-omentectomy have not been previously
studied.
METHODS: Nine patients with type 2 diabetes mellitus and a body mass index ranging from 29 to 34.8 kg/m2
underwent an entero-omentectomy procedure that consisted of an enterectomy of the middle jejunum and exeresis
of the major part of the omentum performed through a mini-laparotomy. Glucagon-like peptide-1 and peptide YY
were measured preoperatively and three months following the operation. Fasting and postprandial variations in
glycemia, insulinemia, triglyceridemia, hemoglobin A1c, and body mass index were determined in the preoperative
period and 3, 18 and, 36 months after the operation.
RESULTS: All patients significantly improved the control of their type 2 diabetes mellitus. Postprandial secretion of
peptide YY and Glucagon-like peptide-1 were enhanced, whereas hemoglobin A1c, fasting and postprandial
glucose, insulin, and triglyceride levels were significantly reduced. Mean body mass index was reduced from 31.1 to
27.3 kg/m2. No major surgical or nutritional complications occurred.
CONCLUSIONS: Entero-omentectomy is easy and safe to perform. A simple reduction in jejunal extension and
visceral fat causes important improvements in the metabolic profile.
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INTRODUCTION
The combination of a vertical gastrectomy, omentectomy
and enterectomy has been proposed as a surgical strategy for
obesity and associated diseases.1 The goals of this method are
to improve gastrointestinal hormone levels rather than cause
mechanical restriction or malabsorption. The results of five
years of experience with this procedure have been published
and are promising, especially in resolving metabolic syn-
drome.1 Indeed, this procedure was proposed in 2002 as the
first surgical technique designed to treat obesity by exclu-
sively aiming at a metabolic rearrangement and avoiding
mechanical restriction (such as prostheses and/or calibrated
anastomoses) and malabsorption.
Vertical gastrectomy adjusts the gastric chamber volume
without narrowing passages to combat the higher caloric
density of a modern diet. Vertical gastrectomy aims to
reduce levels of ghrelin, an orexigenic hormone whose
secretion is supposedly suppressed after meals but is not
properly inhibited in the obese.2,3
Omentectomy leads to purely metabolic actions, and
experimental work has continuously shown that it reduces
insulin resistance.4,5
Jejunectomy has many effects, but the main one is to
diminish nutrient exposure in the proximal gut and move a
significant portion of the absorptive work to the distal small
bowel (as if an unrefined diet were consumed), thereby
enhancing the secretion of Glucagon-like peptide-1 (GLP-1).
GLP-1 and peptide YY (PYY)6 are enterohormones that are
secreted postprandially, satiating and provoking intense
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insulinotropic and glucagonostatic actions.7 Both obese and
type 2 diabetic (T2DM) individuals have a deficiency in the
secretion of GLP-1.8,9
Jejunectomy is possible because there is a very wide
variance of the dimensions of the small bowel;10 an isolated
partial jejunectomy is very safe (a much more extensive
enterectomy is necessary, affecting also the ileum to
generate disease.) Jejunectomies, indeed cause an intense
rise in the production of GLP-1.11
The sum of these interventions, i.e., vertical gastrectomy,
omentectomy and jejunectomy, has beneficial effects on
both obesity and metabolic syndromes without significant
restriction or malabsorption.1
In this model, unlike the vertical gastrectomy, the
enterectomy has received severe criticism. The former was
already part of a well-known procedure, the biliopancreatic
bypass with a duodenal switch. However, based exclusively
on objective data, the opposite result was expected, because
reducing the stomach is more dangerous than reducing the
jejunum. The jejunum has a wider range of dimensions than
the stomach. Vertical gastrectomy alters the organ conforma-
tion and changes the His angle, whereas after a jejunectomy,
as in the proposed pattern, the structure and dimensions of
the small bowel remain within the normal range among
surgery-naı¨ve patients; not even a radiologist could identify
this pattern of partial jejunectomy. Enteric functions are
maintained, and the bowel responds with a strong compen-
satory growth facilitated by Glucagon-like peptide-2 (GLP-2),
another entero-hormone co-secreted with GLP-1.12 None of
these benefits apply to a sleeve gastrectomy.
In addition, biological, physiological, anthropological,
epidemiological, and clinical evidence indicates that the
metabolic damage caused by abundant quantities of refined
food is linked to an overstimulation of the proximal gut and
an understimulation of the distal small bowel. Specifically,
the evolutionary adaptation to a richer diet involves the
selection of smaller abdomens and digestive tracts.13
Finally, when vertical gastrectomy and enterectomy were
performed together,1 all complications were related to the
gastrectomy; none were related to the enterectomy as would
be expected. Therefore, although both may produce very
interesting metabolic effects, there is little doubt that partial
jejunectomies are safer than vertical gastrectomies.
Indeed, vertical gastrectomy is not simple and can cause
severe surgical complications such as fistulas. These
dangers raise the possibility of using just entero-omentect-
omy (EO), the simpler and safer part of the aforementioned
combined procedures, avoiding the sleeve gastrectomy. The
goal would be to improve metabolic parameters, especially
in T2DM. Thus, eliminating the vertical gastrectomy would
significantly reduce the complexity, costs, risk and weight
loss such that merely mildly obese diabetic patients could
benefit.
This study shows and discusses the metabolic effects of
an isolated EO. It presents the results of a research protocol
in mildly obese patients with T2DM who were excluded
from traditional bariatric surgery for exhibiting only ‘‘over-
weight’’ or ‘‘Grade I’’ obesity.
MATERIALS AND METHODS
Patients
The present study includes nine patients with T2DM who
underwent surgery between February and March 2006 and
were followed until the present date. The patients,
diagnosed and treated for T2DM for at least two years,
were between 30 and 60 years of age and had a body mass
index (BMI) between 29 and 34.8 kg/m2. Six of these
patients used insulin; the other three used oral hypoglyce-
mia medication. Moreover, some of the patients used
medications to control hypertension.
The inclusion criteria were as follows: insufficient control
of T2DM with clinical treatment; ability to understand the
procedure and associated risks; having a surgical risk
considered acceptable by the medical assistant (ASA I and
II); and having signed an informed consent form. All
patients were submitted to the same collection methodology
and exams in the preoperative period and 3, 18, and 36
months following surgery.
Technique
The surgery was performed through a mini-laparotomy
with a median supra-umbilical incision of 8 to 10 cm to
release the epiplon from the large gastric curvature while
preserving the gastroepiploic artery. The duodenojejunal
angle was located, measuring 40 cm from the proximal to
the distal end of the jejunum, which remained preserved.
Having located the ileocecal valve, 260 cm of the ileum was
measured in the cranial direction and was also preserved.
The intestine between these two points was measured, and
the enterectomy was then performed. An end-to-end
jejunoileal anastomosis was then performed on two planes,
approximating the mesentery. The small intestine was
measured prior to resection from the duodenal-jejunal angle
to the ileocecal valve.
Anthropometric parameters
Patient weight values were recorded one day prior to
hospital admission and at 3, 18, and 36 months following
surgery. BMI was calculated during the first consultation;
before the surgery, the patients were classified as over-
weight or having Grade I obesity.
Hormonal and laboratory studies
Blood samples of all patients were analyzed after two
different twelve-hour fasting periods. Venous blood sam-
ples were collected after fasting and 30, 60, 90, and 120
minutes after the ingestion of a 300 kcal standard meal
(200 mL NutridrinkH, Nutricia, Bornem, Belgium). Plasma
samples were used to measure GLP-1 and PYY with a
radioimmunoassay at the Hammersmith Hospital in
London as previously described.14 On a different occasion,
after a twelve-hour fast, all nine patients were submitted to
another series of blood sampling: fasting and 1, 2, 3, 4, 5, and
6 hours after the ingestion of a lipid-enriched meal (250 g
meal, 65.95 g of fat, 7 g of carbohydrate, 13.15 g of protein
and 674 total kcal) to measure triglyceride levels. Both the
Nutridrink and the lipid-enriched meal studies were
performed preoperatively and five to six months post-
operatively. Weight loss, changes in bowel habits, feces for
abnormal fat excretion (Sudam III), nutritional parameters
(hemoglobin, albumin, iron, B12 vitamin, and folic acid),
and patient satisfaction were measured on both occasions.
Plasma glucose levels (fasting and 120 min postprandial)
were measured using the hexokinase method; fasting
insulin was measured using immunofluorimetry.
In the preoperative and postoperative evaluations (at 3,
18, and 36 months), glucose levels were determined by
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blood enzymatic colorimetric analysis after 8 to 12 hours of
fasting and also two hours after eating a standardized lunch
containing 414 kcal. Fasting and postprandial insulin
concentrations were determined at the same time as the
glucose by chemoluminescence. Glycated hemoglobin A1c
(HbA1c) levels were determined at the same time as the
fasting glucose level analysis with the method certified by
the US National Glycohemoglobin Standardization Program
using standard reference values (Bio-Rad Variant II HbA1c
Program). The homeostatic model assessment - insulin
resistance (HOMA-IR) index was indirectly derived from
fasting glycemia and insulinemia through the following
equation: HOMA-IR = glycemia (mMol) x insulin (uU/mL)
4 22.5.15 The reference value used for the diagnosis of
insulin resistance by the HOMA–IR index was defined in
the BRAMS study (Brazilian Metabolic Syndrome Study) as
2.71.16
Statistical analysis
Analyses of GLP1, PYY, fasting and postprandial glyce-
mia, fasting and postprandial insulin, HbA1c, HOMA-IR
and BMI were based on the mean values of the laboratory
analyses in the preoperative and postoperative periods.
Linear regression analysis with mixed fixed effects and
random effects was used. The area under the curve (AUC)
was used to assess the peptides GLP1 and PYY. In the
present study, the AUC values were used to identify
changes in the analyzed parameters from the preoperative
period through the three month post-surgical evaluation.
The AUC analysis was conducted using SAS 9.1.3 for
Windows.
To compare each variable of interest (fasting and
postprandial glycemia, fasting and postprandial insulin,
HbA1c, BMI, and HOMA-IR index) over time, an analysis of
variance (ANOVA) for repeated measures was used.
Differences between mean values were compared through
an analysis of residuals; when the supposition of normality
was not satisfied, a logarithmic transformation was per-
formed on the variable. A paired Student’s t-test was used
to compare the variables between evaluation periods. The
level of significance was set at p,0.05.
Nutritional parameters
In the 18th and 36th months after the EO, the patients’
circulating blood was used to determine the following
nutritional values: albumin (g/dL), folic acid (ng/mL),
vitamin B12 (pg/mL), iron (mg/dL), hemoglobin (g/dL),
and globule volume (%). Fecal fat was assessed using a
qualitative study (Sudam III).
Ethical considerations
The study received approval from the Ethics Committee
of the Universidade Estadual de Ponta Grossa (COEP
authorization n .˚ 51/2005, process n .˚ 0416905) and from
the Hospital Vicentino da Sociedade Beneficente Sa˜o
Camilo, where the surgeries were performed. All patients
gave their signed, informed consent.
RESULTS
Surgical results
The total length of the small intestine measured during
surgery, the length and weight of the removed intestinal
segment with the related mesentery and the weight of the
removed epiplon were 7.53¡0.83 meters, 4.53¡0.83 meters
and 892.22¡273.53 grams, and 431.11¡150.70 grams,
respectively (values given as means ¡ standard deviation).
No deaths occurred in the study. Postoperative complica-
tions were restricted to one case of a small incisional hernia
six months following surgery.
Clinical results
Table 1 displays the BMI comparisons between the
preoperative period and the evaluations at 3, 18, and 36
months after surgery. The patients who underwent the EO
exhibited a total weight reduction of 8.43¡2.88% by the 3rd
month, 11.17¡6.33% by the 18th month and 12.07¡7.75% by
the 36th month following the EO.
In the immediate postoperative period, NPH insulin was
suspended, and the patients controlled their diabetes with
regular insulin as needed. The six patients who regularly
used insulin were discharged from the hospital without a
prescription for insulin. After 18 months, no patients were
taking insulin, but three patients were taking oral hypogly-
cemia medication. Arterial hypertension improved in all
eight previously hypertensive patients; five no longer used
medication, and three controlled their hypertension using a
lower dose.
Hormonal assay results
Enterohormones. PYY and GLP-1 secretion were
enhanced in all nine patients. Concentrations of both PYY
and GLP-1 at fasting and at 30, 60, 90, and 120 minutes after
a standard meal were higher in the postoperative period
than before the operation.
The average fasting preoperative GLP-1 was 23.2¡
16.3 pmol/L, whereas the fasting postoperative average
was 33.9¡18.3 pmol/L (p,0.001). Figure 1 shows the
postprandial secretion of GLP-1. The AUC was also
significantly higher postoperatively (4487.43¡2033.8 pmol/
L/min) compared to preoperatively (2657.67¡1436.5 pmol/
L/min) (p=0.005).
Fasting postoperative PYY (13.6¡7.6 pmol/L) was not
statistically higher than preoperative PYY (9.9¡3.6 pmol/L).
However, postprandial secretion of PYY, analyzed by
comparing the AUC after the standard meal, was signifi-
cantly higher (preoperatively 1546.33¡672.32 pmol/L/min;
Table 1 - Comparison of BMI between the preoperative
period and at 3, 18 and 36 months after surgery,
expressed as means and standard deviations. Based on
ANOVA with repeated measures, there is a significant
difference between the initial BMI and the 36-month
postoperative BMI (p= 0.0039).
Patient
Initial
BMI
BMI after 3
months
BMI after 18
months
BMI after 36
months
1 30.3 27.89 27.02 23.15
2 29.5 28.20 27.27 28.60
3 30.5 28.09 28.30 29.02
4 33.8 31.41 31.56 30.09
5 30.3 28.08 28.59 29.40
6 33.2 30.55 30.93 27.73
7 34.8 29.53 26.28 27.05
8 29.1 26.29 24.94 24.96
9 29,0 26.56 24.03 26.01
M (SD) 31.17 (2.18) 28.51 (1.70) 27.66 (2.51) 27.33 (2.28)
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postoperative 2793.17¡1787.68 pmol/L/min; p,0.005), as
shown in Figure 2.
Triglycerides. Analysis of plasma triglycerides showed
that the procedure significantly reduced fasting and
postprandial levels. Figure 3 shows that the AUC was
significantly smaller in the postoperative period (mean
preoperative 79644.00¡27992.67 g/dL/min; mean posto-
perative 42009.00¡16954.33 g/dL/min; p = 0.002).
Other laboratory assay results
Thirty-six months following the EO surgery, there was a
significant reduction in fasting and postprandial glycemia
and insulinemia, HbA1c, and HOMA-IR compared with the
preoperative period (Tables 2, 3, 5, 6, and 4 respectively).
Nutritional aspects
Throughout the 36-month follow-up, the patients did not
exhibit fecal fat at any evaluation, as assessed through a
qualitative investigation (Sudam III). The values of nutri-
tional parameters such as albumin, folic acid and iron were
normal in all patients in the three periods of postoperative
evaluation.
Two female patients exhibited low levels of hemoglobin
and globule volume 18 months after surgery. One reported
not eating red meat due to a taste sensation change; the
other underwent gynecological treatment for 30 days due to
functional metrorrhagia. All patients had serum levels of
vitamin B12 within the normal range. However, one patient
was excluded from the calculation of the B12 mean and
standard deviation because of a chronic intra-muscle B12
replacement as part of a treatment for previous lower limb
neuropathy as directed by a neurologist.
DISCUSSION
The modern diet is related to an intense rise in the
incidence of obesity and T2DM. Refined and concentrated
nutrients comprise much of the modern diet, and refine-
ment is a form of pre-digestion. These resultant high
glycemic index nutrients are rapidly absorbed by the
proximal small intestine, leaving less absorptive work for
the distal gut.
There is much evidence that an overstimulation of the
proximal gut and simultaneous understimulation of the
distal gut might be related to obesity and T2DM.14
Procedures that exclude parts of the foregut are progres-
sively more potent in resolving T2DM. Gastric banding
(which does not exclude the bowel) somewhat improves
T2DM but is dependent on weight loss and takes time.
Roux-en-Y gastric bypass, which excludes part of the
proximal gut, is fast and efficient in resolving T2DM.
However, biliopancreatic bypass, which excludes the entire
duodenum and jejunum, is the most efficient procedure for
resolving obesity, DM2 and dyslipidemia.17
Some researchers who advocate the ‘‘foregut hypothesis’’
attribute this rapid improvement to undiscovered products
of the proximal gut that have an anti-incretinic effect.18
Others, advancing the ‘‘hindgut hypothesis,’’ simply attri-
bute this fast improvement to an enhancement of distal
bowel hormones like GLP-1.19
The evidence supporting the hindgut hypothesis is very
strong. As mentioned, obese and T2DM patients are
deficient in GLP-1.8,9 GLP-1, either endogenous or exogen-
ous, leads to important improvements in T2DM; its
analogues have become an alternative in the medical
treatment of T2DM.
Additionally, the exclusion of the duodenum and
proximal jejunum is not required for fast resolution of
T2DM if the distal gut is flooded with nutrients. For
example, the jejunoileal bypass, an abandoned bariatric
procedure, also caused a fast remission of T2DM20 and an
elevation in the distal bowel hormones that lasted for many
years without a duodenal exclusion.21 However, significant
evidence suggests that the proximal gut plays a role in the
Figure 1 - Mean levels of GLP-1 at fasting and 30, 60, 90, and 120
minutes after a standard meal, pre- and postoperatively.
*p,0.005.
Figure 2 - Mean levels of PYY at fasting and 30, 60, 90, and 120
minutes after a standard meal, pre- and postoperatively.
*p,0.005.
Figure 3 - Mean levels of triglycerides (mg/dL) at fasting and 60,
120, 180, 240, 300, and 360 minutes after a standard meal, pre-
and postoperatively. *p= 0.002.
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development of metabolic syndrome; thus, both the foregut
and hindgut theories are probably correct.
Glucose-dependent insulinotropic polypeptide (GIP) is
hyper-secreted in overeating situations, especially in
response to fatty foods. The obese have an increased
postprandial secretion of GIP.22 GIP is a strong inducer of
fat storage in adipocytes and plays a role in the develop-
ment of obesity; blocking GIP results in a certain protection
against diet-induced obesity.23 GIP is also an incretin, but
T2DM patients are resistant to its incretinic effects.24 With
this resistance, GIP becomes detrimental because its
obesogenic properties remain, but its insulinotropic actions
are inactivated (perhaps because of insufficient confirma-
tory response from GLP-1 and PYY).
The resulting obesity is linked to insulin resistance.
Epidemiological and physiological studies indicate that
those who develop preferentially visceral obesity have a
higher incidence of T2DM.
In sum, recent modifications in the human diet, i.e.,
overabundant and refined foods, have provoked enhanced
absorption in the upper parts of the gut and a reduction in
the distal parts, leading to duodenojejunal hyperactivity and
ileal hypoactivity. A jejunectomy has the potential to
attenuate both problems.
The EO studied here is an auxiliary surgical treatment of
diabetic overweight or Grade I obese patients derived from
the digestive adaptation used in the treatment of morbid
obesity1 but without the use of a vertical gastrectomy. The
final configuration of the gastrointestinal tract looks very
normal because the stomach is untouched, and the small
bowel retains a dimension that is considered normal among
surgery-naı¨ve humans. The transit through the duodenum
and proximal jejunum is preserved, and there are no
obstacles to food ingestion or nutrient absorption. Intes-
tinal segments are not excluded; however, as food more
rapidly reaches the ileum, the penetration of nutrients in the
distal bowel increases, significantly raising GLP-1 and PYY.
The maintenance of the duodenum and proximal jejunum in
transit may avoid protein and micronutrient deficiencies
without compromising the benefits achieved in the im-
provement in T2DM.
There are no reports in the literature regarding any kind
of enteric insufficiency with a partial jejunectomy when the
duodenum, ileum and colon are intact. Indeed, around one
meter of small intestine is sufficient for adequate nutrition
absorption if part of the ileum is preserved and the colon
is present. The proposed resection maintains the bowel
dimensions in a normal range, considering the variation
in human small bowels. As expected, no patient had
diarrhea, signs of poor absorption or malnutrition during
the 36-month follow-up.
Unlike subcutaneous fat, visceral fat has a demonstrated
special relationship with T2DM, insulin resistance, hyper-
tension, dyslipidemia, thrombogenicity and vascular
insults. As visceral fat is insulin resistant, insulin inhibits
lipolysis and keeps releasing free fatty acids (FFA) to the
portal system. It has been suggested that insulin resistance
of the liver is due to the relative increase in the delivery of
FFA from the omental fat depot to the liver.25 Thorne et al.
found an improvement in the metabolism of patients by
adding omentectomy to a common bariatric procedure (i.e.,
gastric banding).26
An omentectomy was added to the procedure to reduce
visceral fat. Visceral adiposity is an important source of
resistin,27 as is plasminogen activator inhibitor 1 (PAI-1)28.
These two substances are linked to an enhanced peripheral
resistance to insulin and atherothrombotic diseases related
to the metabolic syndrome. In 1999, Barzilai et al. showed
that visceral fat excision reduces insulin resistance; this
result has been confirmed by another group.4
All surgical procedures designed to treat T2DM would
probably benefit from the inclusion of an omentectomy
because there is an impressive amount of information
linking visceral fat to T2DM. In addition, there are no
contraindications to the procedure. Indeed, omentectomy
has been performed for many decades as part of the
treatment of gastric and ovarian cancers, with no reports of
complications.
An intense reduction in the triglyceride levels was
observed after the entero-omentectomy, both fasting and
postprandially, as shown in Figure 3. There are at least two
good reasons for this reduction. First, GLP-1 is responsible
for reducing the postprandial rise in triglycerides.29 Second,
in insulin-resistant states, the gut overproduces lipopro-
teins.30 Reducing triglycerides is important in the treatment
of diabetes once fat has inhibited insulin action (Randle’s
effect).31
The EO was also effective in improving systemic arterial
hypertension. Among the eight patients with hypertension,
only three still required drugs for control, and they required
lower doses than before the operation. The remission or
Table 2 - Fasting glycemia: Comparison between
preoperative values and values at 3, 18, and 36 months
after surgery. All postoperative values were significantly
lower (p,0.05). M = mean; (SD) = standard deviation.
Patient
Pre-op
(mg/dl)
After 3
months
(mg/dl)
After 18
months
(mg/dL)
After 36
months
(mg/dl)
1 206 98 128 104
2 114 93 74 86
3 238 132 119 110
4 265 135 121 114
5 98 134 133 138
6 140 120 106 97
7 135 132 87 94
8 211 98 137 123
9 161 123 126 118
M (SD) 174.2 (58.1) 118.3 (17.3) 114.6 (21.5) 109.3 (16.1)
Table 3 - Post-prandial glycemia: Comparison between
preoperative values and values at 3, 18, and 36 months
after surgery. All postoperative values were significantly
lower (p,0.05).
Patient
Pre-op
(mg/dl)
After 3 months
(mg/dl)
After 18 months
(mg/dL)
After 36 months
(mg/dl)
1 491 173 184 179
2 264 188 81 128
3 338 185 143 154
4 265 198 108 160
5 304 117 155 185
6 225 125 68 151
7 311 146 129 135
8 383 160 176 145
9 241 131 152 166
M (SD) 313.6 (82.9) 158.1 (29.8) 132.9 (40.3) 155.9 (18.9)
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better control of hypertension in these patients may be
attributed to reduced fat in the blood and to the correction
of hyperinsulinemia, leading to a possible improvement in
the sympathetic nervous system activity and a lower tubular
absorption of sodium.32 Fat also inhibits the production of
nitrite oxide, an important physiological vasodilator.33
These facts may explain the improvements in arterial
hypertension.
The exact mechanisms by which the surgery proposed
here improves T2DM are unknown. Some studies have
demonstrated that pancreatic exocrine cells incubated with
GLP-1 or exendin-4 differentiate into endocrine phenotype
cells.34 Zhou and colleagues demonstrated that GLP-1 or
exendin-4 induced the pancreatic cell lineage in mice to
differentiate from the original cells into islets of Langerhans
cells.35 These differentiated cells increased the expression of
b-cells genes and the capacity to release insulin. The b-cells
differentiation induced by GLP-1 may be an important
factor in maintaining glucose control in patients who have
undergone EO.
The secretion of intestinal PYY was also significantly
greater postoperatively than preoperatively. PYY is primar-
ily produced by L cells in the intestinal and colonic distal
regions. GLP-1 and PYY release leads to multiple actions,
such as the promotion of the ileal brake, increased release of
glucose-dependent insulin, inhibition of the secretion of
glucagon and increased growth of pancreatic b-cells.36 PYY
also slows down gastric emptying and promotes the ileal
brake activity, clearly contributing to the treatment of
diabetes.
From a surgical standpoint, the EO proposed here is a
simple and inexpensive procedure, as there is a single
entero-anastomosis, with the maintenance of bowel linear-
ity, physiology and nutrient absorption. The risk of
hypoglycemia is low, as the satiation hormones of the distal
intestine are released only as a response to food intake.
All of the patients submitted to EO experienced a
significant improvement in glucose control. Improvements
in glycemia levels occurred immediately following surgery
and led to the suspension of NPH insulin among the six
patients who previously made use of this medication. After
discharge, all patients took oral hypoglycemia medication.
Five patients benefited from monotherapy, whereas four
patients used two drugs to control glycemia. At the 36-
month follow-up, the improvement in fasting and post-
prandial glycemia was maintained (Tables 2 and 3). For
glycemic control, five patients no longer used any medica-
tion, three used monotherapy, and only one used two drugs.
These findings demonstrate that EO was efficient in
improving T2DM.
Based on large epidemiological studies such as the Diabetes
Control and Complications Trial,37 HbA1c is the most
accepted indicator of glycemia as it best reflects the
long-term control of glycemia and predicts co-morbidities.
In the preoperative period, all patients were under clinical
treatment for T2DM, but the control of A1c proved
inadequate, with a mean value of 10.15¡1.39%. At three, 18
and 36 months following surgery, the mean values were
6.76¡0.85%, 6.82¡0.65% and 6.49¡0.68%, respectively,
demonstrating a significant difference over time in relation
to the preoperative period (Table 4).
These results are eloquent in terms of the physiopathol-
ogy. They clearly indicate that a reduction of the jejunum
and visceral fat improves diabetes through metabolic
changes, without significant malabsorption. As it is extre-
mely simple, EO might be considered as an auxiliary
treatment to poorly controlled T2DM in some areas with
no access to advanced medicine. Alternatively, EO may be
added to other more complex surgical procedures to reliably
cause complete remission of T2DM in the long term.
Table 4 - Glycated hemoglobin (HbA1c%): Comparison
between preoperative values and values at 3, 18, and 36
months after surgery. All postoperative values were
significantly lower (p,0.05). M = mean; (SD) = standard
deviation.
Patient
Pre-op
(mg/dl)
After 3
months(mg/dl)
After 18
months (mg/dL)
After 36
months (mg/dl)
1 11.49 8.20 7.0 7.2
2 8.16 5.80 6.7 5.6
3 9.20 6.80 6.2 6.6
4 8.90 7.70 7.4 6.8
5 9.00 7.40 7.2 7.4
6 12.20 6.40 6.6 6.3
7 10.44 6.60 5.6 5.3
8 11.30 6.16 7.8 6.5
9 10.65 5.80 6.9 6.7
M (SD) 10.15 (1.39) 6.76 (0.85) 6.82 (0.65) 6.49 (0.68)
Table 5 - Fasting insulin levels: Comparison between
preoperative values and values at 3, 18, and 36 months
after surgery. All postoperative values were significantly
lower (p,0.05). M = mean; (SD) = standard deviation.
Patient
Pre-op
(mU/dl)
After 3
months (mU/dl)
After 18
months (mU/dl)
After 36
months (mU/dl)
1 32.5 16.8 8.5 8.3
2 29.8 5.3 18.2 10.4
3 10.9 17.2 9.8 8.6
4 17.5 13.2 10.1 8.0
5 16.7 6.3 5.5 4.8
6 19.3 25.7 7.6 8.4
7 56.2 9.0 3.1 3.0
8 12.0 3.1 5.2 3.4
9 15.5 3.8 4.4 5.0
M (SD) 35.4 (34.6) 14.3 (9.4) 8.0 (4.5) 6.7 (2.6)
Table 6 - Post-prandial insulin levels: Comparison
between preoperative values and values at 3, 18, and 36
months after surgery. All postoperative values were
significantly lower (p,0.05). M = mean; (SD) = standard
deviation.
Patient
Pre-op
(mU/dl)
After 3
months (mU/dl)
After 18
months (mU/dl)
After 36
months (mU/dl)
1 56.0 41.1 30.0 38.0
2 67.0 18.4 8.3 14.1
3 51.6 66.2 22.6 17.7
4 113.0 62.4 9.3 16.8
5 22.6 28.7 15.8 19.3
6 65.5 79.6 17.9 15.2
7 64.9 52.0 9.9 15.9
8 191.0 58.8 8.9 10.0
9 45.1 11.9 10.9 12.2
M (SD) 75.2 (49.6) 46.6 (23.1) 14.8 (7.5) 17.7 (8.1)
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CONCLUSION
The metabolic effects of reducing the jejunum and visceral
fat are beneficial in mildly obese, T2DM patients. There are
no obstacles to food intake, no prosthesis, no excluded
segment and no malabsorption. The general structure and
functions of the digestive tract are maintained with this
surgery. GLP-1 and PYY secretion increased, while fasting
and postprandial glycemia, triglyceride levels, and HbA1c
were significantly reduced. A slight weight loss was
obtained with no need for nutritional support. Isolated EO
has positive effects on the metabolic profile of metabolic
syndrome patients. As it is simple, safe and inexpensive, the
procedure may be considered as an auxiliary treatment for
T2DM. Additionally, it may be considered in conjunction
with other metabolic active procedures.
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